In this free webinar, learn about improving the quality of life and bringing more effective and affordable treatments to patients through one-stop R&D solutions for ophthalmology gene therapy. Attendees will gain insights into the rapid advancements in preclinical ophthalmic gene therapy research. The featured speaker will discuss how artificial intelligence (AI)-guided AAV design tools can help accelerate the development of effective therapeutics for patients with ophthalmic diseases.
TORONTO, Ontario, May 19, 2023 /PRNewswire-PRWeb/ -- There are a large number of patients with hereditary ophthalmic diseases worldwide, with gene therapy drugs emerging as a powerful therapeutic tool in ophthalmology due to the limited efficacy of traditional treatments. As of 2021, ophthalmology ranks second in the gene therapy pipeline according to the number of treatments in development. There are many gene therapy drugs currently on the market, but basic research and clinical translation in ophthalmology face many difficulties, such as complicated operations, a long production period for experimental models and expensive equipment.
With the continuous progress of gene-editing technology and the development of new delivery methods, the future of gene therapy for ocular diseases is very promising. Despite the complicated operations, a long production period for experimental models and expensive equipment, companies and institutions are actively investing in research and development, and increasing numbers of clinical trials are being conducted to validate the safety and efficacy of these new treatments. The goal is to bring more effective and affordable treatments to patients with hereditary ophthalmic diseases and to improve their quality of life.
Register for this webinar to learn about the rapid advancements in preclinical ophthalmic gene therapy research, such as how AI-guided AAV design tools can help accelerate development of effective therapeutics to patients with ophthalmic diseases.
Join Joseph Wekselblatt, Senior Scientific Business Development Manager at Cyagen Biosciences, for the live webinar on Friday, June 9, 2023, at 1pm EDT (10am PDT).
For more information, or to register for this event, visit Accelerating Gene Therapy for Ophthalmic Diseases.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article